普冉股份(688766.SH):上半年公司ETOX Flash營收佔比逐步提升
格隆匯9月1日丨有投資者向普冉股份(688766.SH)提問:請問公司目前不同工藝架構產品的出貨情況?
普冉股份回覆:上半年公司 ETOX Flash 營收佔比逐步提升;SONOS 平台下,40nm 製程產品收入佔比同步提升。公司 256M 大容量 Flash已量產出貨。
未來隨着公司 512M-1G 容量產品的逐步推出,公司將在 128M以上大容量市場持續發力,在鞏固中小容量產品的市場份額基礎上,實現大容量的快速放量,將同步提升公司現有產品的 ASP 和毛利率水平。謝謝!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.